Targeted therapy using alpha particles for neuroendocrine tumors
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
This study is testing a new treatment for people with advanced neuroendocrine tumors that uses a special type of radiation to help shrink tumors more effectively than current options, and it aims to create a personalized approach based on imaging to ensure safety and effectiveness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10850995 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for patients with advanced neuroendocrine tumors using a targeted radionuclide therapy that employs alpha particles. The therapy aims to improve tumor regression and potentially achieve complete responses, which are rare with current treatments. The study will involve optimizing the production of a specific radiopharmaceutical and conducting preclinical trials to assess its safety and effectiveness. Patients may benefit from personalized therapy guided by imaging techniques that measure radiation dose accurately.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced neuroendocrine tumors who have not responded adequately to existing therapies.
Not a fit: Patients with early-stage neuroendocrine tumors or those who have not been diagnosed with this type of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced neuroendocrine tumors, potentially leading to better outcomes and quality of life.
How similar studies have performed: There is emerging evidence suggesting that therapies using alpha-emitters have shown promise in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Menda, Yusuf — University of Iowa
- Study coordinator: Menda, Yusuf
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.